USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
STC BIOLOGICS, INC
Address:
763 D Concord Ave
CAMBRIDGE, MA 02138
Phone:
N/A
URL:
EIN:
264335683
DUNS:
829731814
Number of Employees:
7
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $299,881.00 1
SBIR Phase II $2,499,488.00 1

Award List:

Not Available

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$299,881.00
Agency:
HHS
Principal Investigator:
Magdalena Leszczyniecka – (617) 899-0724
Abstract:
The goal of this project is to develop STC trastuzumab, a generic version of Herceptin. Trastuzumab is a monoclonal antibody made against the HER2 protein that is overexpressed in 20-25% of patients with breast cancer. Because of very high cost associated with prescribing Herceptin, a generic… More

IGF::OT::IGF SBIR PHASE II TOPIC 275, DEVELOPMENT OF GENERIC TRASTUZUMAB FOR THE TREATMENT OF BREAST CANCER.

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$2,499,488.00
Agency:
HHS
Principal Investigator:
Magdalena Leszczyniecka – 617-899-0724
Abstract:
The goal of this project is to develop STC101, a biosmilar Herceptin . Trastuzumab is a monoclonal antibody made against the HER2 protein that is overexpressed in 20-25% of patients with breast cancer. Because of high cost associated with prescribing Herceptin , a generic version of this drug would… More